Anticoagulant rat poison: the vitamin K mistake everyone makes

A two-year-old is brought in because his mother found him with a handful of blue rat-poison pellets. He is completely well. The clotting screen is normal. The instinct is to give a dose of vitamin K and feel that something useful has been done.

That instinct is the single commonest error in this poisoning, and the consensus guideline addresses it directly:

The administration of vitamin K is not recommended prior to evaluation for coagulopathy. (Grade D)

Prophylactic vitamin K masks the onset and severity of the poisoning and destroys the value of the one test that would have told you whether this child needed nothing at all or months of treatment. When the guideline panel surveyed US poison centres, not one recommended prophylactic vitamin K.

Why the INR on arrival tells you nothing

Long-acting anticoagulant rodenticides inhibit vitamin K 2,3-epoxide reductase and vitamin K quinone reductase, preventing activation of factors II, VII, IX and X. The prothrombin time only prolongs once those factors fall below 25–30% of normal — and there are perfectly good clotting factors already circulating at the moment of ingestion. So the onset of anticoagulation is delayed by hours to days.

The PT or INR is the best screening test when performed 48–72 hours after exposure.

The supporting number is stark. In a prospective series, prothrombin times taken at 48 hours were abnormal in 17% of cases, versus 1.9% at 24 hours. A single PT at 24 hours would have missed four of eight cases.

A normal INR at 48–72 hours is what excludes a toxic ingestion. The one on admission is not that test.

Who actually needs hospital

The guideline gives graded triage criteria. Three groups go to an emergency department immediately, regardless of the dose reported:

• Suspected self-harm, abuse, misuse or malicious administration (Grade D)
• Any symptoms — bleeding, bruising (Grade C)
• Chronic ingestion, for evaluation of intent and coagulopathy (Grade B). An acute ingestion means any number of ingestions within up to 8 hours; anything longer is chronic.

Two groups need timed bloods rather than immediate referral: patients already on therapeutic anticoagulants, who need a baseline PT and a repeat at 48–72 hours (Grade D); and asymptomatic patients with unintentional ingestion of 1 mg or more of active ingredient, evaluated for coagulopathy at 48–72 hours (Grade B). Outpatient monitoring only works where coagulation results come back in under 24 hours.

And the largest group needs nothing:

Patients with unintentional ingestion of less than 1 mg of LAAR active ingredient can be safely observed at home without laboratory monitoring. This includes practically all unintentional ingestions in children less than 6 years of age. (Grade C)

The child who ate the bait

The evidence behind that recommendation is unusually reassuring. Of more than 20,000 unintentional childhood exposures reviewed for the guideline, only 14 had a prolonged PT-INR — range 1.22 to 2.6 — and none demonstrated bleeding. Only one exceeded an INR of 2. A 20-year review of the US poison-centre database found no LAAR-related deaths in children under six.

That applies to an acute, unintentional ingestion of a ready-to-use bait. It does not apply to a deliberate ingestion, a chronic one, or a child who is already bleeding — each of those goes to hospital regardless of dose.

One caution specific to us: the 1 mg threshold assumes US consumer products, where brodifacoum is usually formulated at 0.005%. Available concentrations range from 0.005% to 99%, and the guideline states explicitly that it was developed for US conditions and should not be extrapolated elsewhere unless those conditions hold. Read the label on the product actually ingested.

What not to do

No ipecac, no gastric lavage (Grade D). In a reported case, ipecac caused severe vomiting followed by subarachnoid haemorrhage and death in an adult with brodifacoum poisoning. Straining to vomit in an anticoagulated patient is its own mechanism of injury.

Do not delay transport for activated charcoal (Grade D). No human study has assessed charcoal binding for these compounds; in paediatric unintentional ingestions there was no outcome difference between those who received any decontamination and those who did not.

Do not overlook skin exposure (Grade D). One man developed haematuria and a markedly prolonged PT a week after spilling a concentrated liquid formulation into his boot and continuing to wear it. Wash exposed skin with mild soap and water.

Vitamin K1, once coagulopathy is documented

It treats the coagulopathy. It does not remove the poison, and the poison outlasts it.

Oral is the preferred route, and not merely for convenience. Intravenous phytomenadione carries a black box warning for anaphylactoid reactions that have been associated with fatalities — around 3 per 10,000 doses, attributed to the polyethoxylated castor oil vehicle rather than to vitamin K itself. Reserve the intravenous route for serious bleeding, and give it slowly and diluted.

Dose is titrated against the INR, not fixed. A commonly cited oral starting point in documented coagulopathy is 100 mg per day in four divided doses, with reported total daily doses ranging from about 25 mg to 400 mg. Divided dosing matters — a less frequent regimen may not be effective, because the antagonist outlasts each dose of vitamin K.

Active bleeding is a different problem

Vitamin K1 takes hours to work, because clotting factors must be resynthesised. For active or life-threatening haemorrhage, replace factors — fresh frozen plasma or prothrombin complex concentrate — alongside vitamin K1, not instead of it. Recombinant activated factor VII has been used in a small number of patients, and therapeutic plasma exchange has been used as second-line after an anaphylactoid reaction to vitamin K. The guideline notes there are no prospective or controlled data supporting the efficacy of any of these measures.

This one is measured in months

Serum brodifacoum half-life ran from 16 to 34 days after overdose, and the duration of action ranged from 46 days to 9 months. Treatment with vitamin K was often required for weeks to months. Do not plan a one-week course.

Expect rebound coagulopathy when the dose is reduced or stopped — recheck the INR after each step down, not only at the end. Where serum concentrations can be obtained, they help decide when to stop; coagulopathy is unlikely below 10 ng/mL for brodifacoum. And flag one thing for the future: supplemental vitamin K can persist for up to two weeks and will interfere with subsequent therapeutic anticoagulation if the patient later needs warfarin.

Compliance is part of the treatment. A patient who quietly stops taking vitamin K at home after a deliberate ingestion stays at risk for months, which makes follow-up and the psychiatric assessment structural rather than optional.

Bottom line

Do not give vitamin K until you have documented a coagulopathy. Do not trust the admission INR — the test is at 48 to 72 hours. Deliberate, symptomatic and chronic ingestions go to hospital regardless of dose; a small accidental ingestion in a young child almost certainly needs nothing. No ipecac, no lavage, and do not delay transport for charcoal. Prefer oral vitamin K1 in divided doses. And plan for months, not days.

Our anticoagulant rat poison tool implements these triage criteria directly — tick what applies and it returns the guideline's verdict with its grade. If you are not sure which rat poison was taken, start with the wheat pill and rat poison tool, because phosphide kills within hours and is an entirely different problem. Also in the suite: Harpic and corrosives and copper sulphate.

ReviseFCPS1 is built by doctors in Pakistan, for doctors in Pakistan. All our clinical tools are free. If you are preparing for FCPS Part 1, try it free for 7 days — 10,176 doctor-verified MCQs and 8,236 real exam recalls.